Clinical Observation of Qingying powder Intervention in Hashimoto thyroiditis with normal thyroid function

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100005311

Enrollment

Unknown

Registered

2021-09-15

Start date

2021-09-13

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto thyroiditis

Interventions

Control group:selenious yeast tablets

experimental group:Qingying powder

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Comply with the diagnostic criteria of hashimoto's thyroiditis, TCM syndrome differentiation is liver spleen deficiency type; ? Adult patients aged 20 to 65 years, both male or female; ? Thyroid peroxidase antibody(TGAb) >300 IU/ml; ? Triiodothyronine(T3), thyroxine(T4),thyroid-stimulating hormone(TSH) were normal; ? Signing informed consent.

Exclusion criteria

Exclusion criteria: ? Pregnant or lactating women; ? Anemia (male: hemoglobin<120g/L, female: hemoglobin<110g/L); ? Patients with autoimmune hepatitis, chronic glomerulonephritis and other autoimmune diseases; ? Patients received drugs that may affect the conversion of thyroxine to triiodothyronine, may affect thyroid autoimmune drug therapy including corticosteroid, amiodaron, propranolol, a-interferon, etc; ? Osteoporosis; ? Patients with mental illness.

Design outcomes

Primary

Measure	Time frame
thyroid peroxidase antibody;thyroglobulin antibody;	—

Secondary

Measure	Time frame
quality of life;TCM Symptom Score;thyroid volume;thyroid function;	—

Countries

China

Contacts

Public ContactChen yi

gogo1st@163.com18116070305

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026